BR112023019896A2 - Vetores e método para triagem de proteína funcional de ligação ao antígeno - Google Patents
Vetores e método para triagem de proteína funcional de ligação ao antígenoInfo
- Publication number
- BR112023019896A2 BR112023019896A2 BR112023019896A BR112023019896A BR112023019896A2 BR 112023019896 A2 BR112023019896 A2 BR 112023019896A2 BR 112023019896 A BR112023019896 A BR 112023019896A BR 112023019896 A BR112023019896 A BR 112023019896A BR 112023019896 A2 BR112023019896 A2 BR 112023019896A2
- Authority
- BR
- Brazil
- Prior art keywords
- binding protein
- functional antigen
- antigen
- vectors
- screening functional
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 7
- 238000012216 screening Methods 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000025171 antigen binding proteins Human genes 0.000 abstract 7
- 108091000831 antigen binding proteins Proteins 0.000 abstract 7
- 239000012634 fragment Substances 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000002823 phage display Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
vetores e método para triagem de proteína funcional de ligação ao antígeno. um método para selecionar uma proteína funcional de ligação ao antígeno. o método compreende a etapa de construir um vetor de expressão, por meio de uma técnica de exibição de fago e/ou uma técnica de exibição celular, usando uma cadeia leve ou um fragmento da mesma, de uma proteína de ligação ao antígeno de referência com uma sequência e função conhecidas, ou uma cadeia pesada ou um fragmento da mesma, da proteína de ligação ao antígeno de referência, selecionando assim uma proteína funcional de ligação ao antígeno que se liga ao mesmo epítopo que a proteína de ligação ao antígeno de referência. é fornecida ainda uma proteína funcional de ligação ao antígeno obtida por meio do método.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110350207 | 2021-03-31 | ||
| PCT/CN2022/084229 WO2022206868A1 (zh) | 2021-03-31 | 2022-03-30 | 用于筛选功能性抗原结合蛋白的载体和方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023019896A2 true BR112023019896A2 (pt) | 2023-11-07 |
Family
ID=83458026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023019896A BR112023019896A2 (pt) | 2021-03-31 | 2022-03-30 | Vetores e método para triagem de proteína funcional de ligação ao antígeno |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4317549A1 (pt) |
| JP (1) | JP2024513871A (pt) |
| KR (1) | KR20230164128A (pt) |
| CN (1) | CN117136258A (pt) |
| BR (1) | BR112023019896A2 (pt) |
| MX (1) | MX2023011638A (pt) |
| WO (1) | WO2022206868A1 (pt) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US20090258013A1 (en) | 2008-04-09 | 2009-10-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
| EP2692865B1 (en) * | 2012-07-30 | 2014-12-10 | NBE-Therapeutics LLC | Transposition-mediated identification of specific binding or functional proteins |
| CN103806112A (zh) * | 2013-06-09 | 2014-05-21 | 南京中医药大学 | 一种噬菌体展示随机肽库的构建方法 |
| TW201902462A (zh) | 2017-06-02 | 2019-01-16 | 瑞士商赫孚孟拉羅股份公司 | 用於免疫促效劑之新穎投與途徑 |
| JP2022516647A (ja) * | 2019-01-07 | 2022-03-01 | クリスプ－エイチアール セラピューティクス， インコーポレイテッド | 非毒性ｃａｓ９酵素およびその用途 |
| JP2022532699A (ja) | 2019-04-22 | 2022-07-19 | ディーディービオ カンパニー リミテッド （シャンハイ） | ファージライブラリーを調製する方法 |
-
2022
- 2022-03-30 BR BR112023019896A patent/BR112023019896A2/pt unknown
- 2022-03-30 MX MX2023011638A patent/MX2023011638A/es unknown
- 2022-03-30 EP EP22779050.8A patent/EP4317549A1/en active Pending
- 2022-03-30 CN CN202280025128.6A patent/CN117136258A/zh active Pending
- 2022-03-30 JP JP2023561051A patent/JP2024513871A/ja active Pending
- 2022-03-30 KR KR1020237037214A patent/KR20230164128A/ko unknown
- 2022-03-30 WO PCT/CN2022/084229 patent/WO2022206868A1/zh active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023011638A (es) | 2023-10-13 |
| WO2022206868A1 (zh) | 2022-10-06 |
| JP2024513871A (ja) | 2024-03-27 |
| CN117136258A (zh) | 2023-11-28 |
| EP4317549A1 (en) | 2024-02-07 |
| KR20230164128A (ko) | 2023-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000461A1 (es) | Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador. | |
| BR112017014308A2 (pt) | anticorpos biespecíficos contra calicreína plasmática e fator xii | |
| CL2016000324A1 (es) | Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1. | |
| PE20221282A1 (es) | Anticuerpos que se unen a hla-a2/mage-a4 | |
| UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
| BR112021026890A2 (pt) | Composições de anticorpo para interromper biofilmes | |
| CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
| CL2022000142A1 (es) | Proteínas que comprenden dominios de unión a antígeno de la peptidasa 2 relacionada con la calicreína y sus usos. | |
| BR112022011669A2 (pt) | Anticorpos biespecíficos caninizados e parceiros de ligação biespecíficos para tratar dermatite atópica | |
| BR112021023897A2 (pt) | Anticorpo ou receptor de antígeno quimérico que visa claudina18.2 | |
| CO2022008407A2 (es) | Anticuerpos específicos para cd47, pd–l1 y sus usos | |
| BR112021013397A2 (pt) | Anticorpos anti-tigit | |
| PE20181199A1 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
| BR112018072140A2 (pt) | anticorpos anti-basigin humanizados e uso dos mesmos | |
| PE20230374A1 (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
| BR112023000826A2 (pt) | Anticorpo anti-ctla-4 e uso do mesmo | |
| CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| PE20230839A1 (es) | Agentes de union a lair-1 y metodos para su uso | |
| BR112019004901A2 (pt) | anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, seu método de preparação, molécula de ácido nucleico, vetor recombinante, célula hospedeira, kit de diagnóstico e método para fornecer informações | |
| BR112023019896A2 (pt) | Vetores e método para triagem de proteína funcional de ligação ao antígeno | |
| BR112019009765A2 (pt) | anticorpo de ligação à anidrase carbônica e uso do mesmo | |
| BR112021011529A2 (pt) | Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado | |
| UY39798A (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| BR112017008011A2 (pt) | métodos baseados em proximidade para seleção de parceiros de ligação | |
| BR112022009611A2 (pt) | Anticorpos anti-ror-2 e métodos de uso |